Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucarpidase for delayed clearance of high-dose methotrexate (CPG2-PII)
jRCT2091220097Phase 2Completed
- Sponsor
- Hiroshi Kawamoto
- Start
- Sep 2012
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glucarpidase in Methotrexate overdose and acute kidney failure (AKF), sponsored by Hiroshi Kawamoto. Primary endpoint: Rapid and sustained methotrexate clinically important reduction (CIR proportion). Started Sep 2012; status: completed.
02
Drugs
glucarpidase
03
Conditions
Methotrexate overdoseacute kidney failure (AKF)
Beyond the preview
Go deeper on jRCT2091220097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220097.